Skip to main content
. Author manuscript; available in PMC: 2022 May 7.
Published in final edited form as: J Cyst Fibros. 2019 Aug 23;19(2):284–291. doi: 10.1016/j.jcf.2019.08.001

Figure 2. Primary endpoint of relative change from baseline to day 168 in FEV1 (per-protocol population).

Figure 2.

a LS mean difference (ALIS–TIS) adjusted for treatment and randomisation strata at day 168 was −1.31% (95% CI −4.95 to 2.34; P = .48). The lower bound of the 95% CI was > −5%, indicating noninferiority of ALIS to TIS.

ALIS, amikacin liposome inhalation suspension; FEV1, forced expiratory volume in 1 second; LS, least squares; TIS, tobramycin inhalation solution.